Right heart biopsy during device placement to detect cardiac amyloidosis
Part of Brain & nervous system, Genetic & congenital, Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether taking a small tissue sample from the right side of the heart during a routine pacemaker or defibrillator procedure can help find a condition called cardiac amyloidosis, which causes stiffening of the heart muscle. It aims to improve early detection in people who already need a cardiac device and may have early signs of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years or older, or between 50 and 64 if you have a family history of ATTR amyloidosis or a known genetic variant.
- You must have a medical need for a pacemaker, ICD, or CRT device.
- You must have at least one of a list of conditions, including certain heart rhythm problems, heart failure, thickened heart muscle, unexplained kidney issues, nerve pain, carpal tunnel syndrome, tendon rupture, or other related findings.
- You cannot participate if you are pregnant or unable to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls patients suspected of having or recently diagnosed with cardiac amyloidosis—a condition where abnormal protein deposits thicken the heart muscle. Researchers will use imaging tests like echocardiography and MRI to better understand the disease and track how it changes over time, which may improve future treatment options.
This study tests if a pacemaker or defibrillator can spot a rare heart condition called cardiac amyloidosis by measuring electrical signals in the right ventricle. It might help people with thickened heart walls find out sooner if they have this treatable disease.
This study tests if setting a pacemaker to a faster heart rate (70 beats per minute) can help people with a specific type of heart disease called ATTR cardiac amyloidosis. It is for people who already have a pacemaker and have heart failure symptoms.
This study uses a new imaging technique (PET scan with a tracer called evuzamitide) to detect a type of heart disease called cardiac amyloidosis in patients whose standard heart scans were unclear but who have elevated levels of a new blood marker (TAD1). The goal is to find a better way to diagnose this condition.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.